Beverly, MA - Freudenberg Medical, a global contract design, development and manufacturing partner to the medical device and biopharma industry, has announced a strategic leadership transition. Effective January 1, 2025, Michael McGee, former COO, assumed the role of Chief Executive Officer, succeeding Dr. Mark Ostwald, who transitioned to another leadership role within the Freudenberg Group.
CEO Transition: Michael McGee takes over from Dr. Mark Ostwald
Effective January 1, 2025, Michael McGee, former COO, assumed the role of Chief Executive Officer at Freudenberg Medical, succeeding Dr. Mark Ostwald.
Hemoteq Transitions to the Freudenberg Medical Brand
Full brand integration to strengthen “One Freudenberg Medical” as a vertically integrated, strategic partner to global MedTech companies
BEVERLY, Massachusetts – January 15, 2026 --Hemoteq AG has been part of the Freudenberg Medical Group of companies since 2015. During this time, Hemoteq has successfully operated under a dual-brand strategy as Hemoteq – a company of Freudenberg Medical. This approach ensured continuity for customers and partners while enabling close operational and strategic integration.
In 2025, the Freudenberg Group became the sole owner of Hemoteq AG. Hemoteq transitioned to the Freudenberg Medical brand in January 2026 to reflect the fully integrated organization and to further strengthen a unified market presence.
This brand transition underscores the strength of “One Freudenberg Medical”: a vertically integrated offering spanning silicone, thermoplastic, and metal components, through to the development and manufacturing of minimally invasive medical devices and advanced medical coatings. Bringing all capabilities under one strong brand enables clearer positioning, greater transparency, and a more consistent customer experience worldwide.
Michael McGee joined Freudenberg Medical as COO in 2022, bringing more than 30 years of experience in the medical device industry. His appointment to CEO reflects Freudenberg’s commitment to continuity and alignment with the company’s values and long-term strategy.
Under Michael McGee’s leadership, Freudenberg Medical continues to prioritize customer-centricity by investing in advanced technologies, people and processes. “Since joining Freudenberg Medical, I have been deeply inspired by our company values and our talented global team with proven expertise in materials and technologies. Together, we will build on this strong foundation and drive meaningful advancements in healthcare,” McGee stated. “We remain steadfast in delivering consistent strategic partnership and prioritizing customer success.”
Former CEO Dr. Mark Ostwald served Freudenberg Medical for 16 years in various leadership roles. During his tenure, the company doubled its annual revenue, expanded its global manufacturing footprint by one-third, and integrated three Joint Ventures. “Leading this extraordinary organization was an honor and a privilege,” said former CEO Dr. Mark Ostwald. “Michael is passionately committed to our strategy and values, developing our people and delivering high-quality products to improve patients’ lives. I am convinced that Michael is the right leader to take Freudenberg Medical to the next level of success.”
"Mark Ostwald’s leadership has been instrumental in shaping Freudenberg Medical’s success. His strategic vision and dedication solidified the company’s reputation as a trusted strategic partner in the medical device and pharmaceutical industries.
Michael McGee has already demonstrated his ability to drive results and success. The Board of Management is confident that under his leadership, Freudenberg Medical will continue to grow, innovate, and thrive."
Dr. Mohsen Sohi
Freudenberg Group CEO and Speaker of the Management Board
Press contact:
LAURA KIRSTEIN
Director of Marketing and CommunicationsMAURA LEAHY
Strategic Marketing Manager Minimally Invasive Solutions